Cormorant Asset Management’s Puma Biotechnology PBYI Stock Holding History

Cormorant Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-167,300	Closed	-$39.5M	–	82
2015 Q1	$39.5M	Sell	167,300 -52,700	-24%	-$11.3M	6.1%	3
2014 Q4	$41.6M	Sell	220,000 -287,500	-57%	-$63.8M	6.42%	2
2014 Q3	$121M	Buy	507,500 +300,000	+145%	+$61.6M	24.9%	1
2014 Q2	$13.7M	Hold	207,500	–	–	3.63%	9
2014 Q1	$21.6M	Buy	207,500 +7,500	+4%	+$882K	4.97%	3
2013 Q4	$20.7M	Buy	+200,000	New	+$11.7M	6.01%	5

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cormorant Asset Management's PBYI Position: Q2 2015 in Review

Cormorant Asset Management sold out of Puma Biotechnology (PBYI) in Q2 2015, closing a stake of 167,300 shares — an estimated $39.5M sold.

Cormorant Asset Management first reported a position in PBYI in Q4 2013 and held it in 6 quarters. The position peaked at $121M in Q3 2014. 198 funds tracked by Wall St. Rank hold PBYI as of Q2 2015.

Cormorant Asset Management reported no remaining Puma Biotechnology position as of Q2 2015 after selling out during the quarter.
Cormorant Asset Management sold 167,300 Puma Biotechnology shares in Q2 2015, an estimated $39.5M.
Cormorant Asset Management first reported a position in Puma Biotechnology in Q4 2013 and held it in 6 quarters.
Cormorant Asset Management's Puma Biotechnology position peaked at $121M in Q3 2014.
198 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2015.

Based on Cormorant Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.